Evidence map›Paper›PMID 38412124›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis.

Takehiko Oami, Shabnam Abtahi, Takashi Shimazui, Ching-Wen Chen, Yan Y Sweat, Zhe Liang, Eileen M Burd, Alton B Farris, Joe T Roland, Sachiko Tsukita and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Tight Junction Defects in Aganglionic and Ganglionic Colon in Children With Hirschsprung Disease.Laboratory investigation; a journal of technical methods and pathology · 2026
    Article
  9. Article
  10. Review
  11. Frontiers in microbiology · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Takehiko Oami *Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA 30322.
Shabnam Abtahi *Laboratory of Mucosal Pathobiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Takashi ShimazuiDepartment of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0003-0885-9437
Ching-Wen ChenDepartment of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA 30322.
Yan Y SweatLaboratory of Mucosal Pathobiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Zhe LiangDepartment of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA 30322.
Eileen M BurdDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0002-7055-942X
Alton B FarrisDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0001-5534-7763
Joe T RolandEpithelial Biology Center, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37240.
Sachiko TsukitaAdvanced Comprehensive Research Organization, Teikyo University, Tokyo 173-0003, Japan.ORCID 0000-0003-2916-0772
Mandy L FordDepartment of Surgery and Emory Transplant Center, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0001-6736-4421
Jerrold R TurnerLaboratory of Mucosal Pathobiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-0627-9455
Craig M CoopersmithDepartment of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0003-2400-3217
Emory University · USBrigham and Women's Hospital · USTeikyo University · JPVanderbilt University Medical Center · US

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
ZO-1-MEDIATED PROTEIN INTERACTIONS: REGULATORS AND INTEGRATORS OF DIVERSE EPITHELIAL FUNCTIONS IN HEALTH AND DISEASER01DK061931 · NIDDK · UNIVERSITY OF CHICAGO · PI JERROLD R. TURNER · 2001 to 2026
$15.0M
Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.R01DK068271 · NIDDK · UNIVERSITY OF CHICAGO · PI JERROLD R. TURNER · 2005 to 2026
$11.3M
Mechanisms of Intestinal Integrity in Sepsis and ShockR01GM072808 · NIGMS · WASHINGTON UNIVERSITY · PI COOPERSMITH, CRAIG M · 2005 to 2021
$5.1M
The Gut as a Target to Improve Outcomes in SepsisR35GM148217 · NIGMS · EMORY UNIVERSITY · PI Craig M Coopersmith · 2023 to 2026
$2.2M
Memory T Cell Cosigning Pathways in Sepsis-Induced Immune DysregulationR01AI149724 · NIAID · EMORY UNIVERSITY · PI FORD, MANDY L · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI149724NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK061931NIDDK NIH HHS R01 DK068271NIGMS NIH HHS R01 GM072808NIGMS NIH HHS R35 GM148217
6 · The paper itself

Abstract

Intestinal epithelial expression of the tight junction protein claudin-2, which forms paracellular cation and water channels, is precisely regulated during development and in disease. Here, we show that small intestinal epithelial claudin-2 expression is selectively upregulated in septic patients. Similar changes occurred in septic mice, where claudin-2 upregulation coincided with increased flux across the paracellular pore pathway. In order to define the significance of these changes, sepsis was induced in claudin-2 knockout (KO) and wild-type (WT) mice. Sepsis-induced increases in pore pathway permeability were prevented by claudin-2 KO. Moreover, claudin-2 deletion reduced interleukin-17 production and T cell activation and limited intestinal damage. These effects were associated with reduced numbers of neutrophils, macrophages, dendritic cells, and bacteria within the peritoneal fluid of septic claudin-2 KO mice. Most strikingly, claudin-2 deletion dramatically enhanced survival in sepsis. Finally, the microbial changes induced by sepsis were less pathogenic in claudin-2 KO mice as survival of healthy WT mice injected with cecal slurry collected from WT mice 24 h after sepsis was far worse than that of healthy WT mice injected with cecal slurry collected from claudin-2 KO mice 24 h after sepsis. Claudin-2 upregulation and increased pore pathway permeability are, therefore, key intermediates that contribute to development of dysbiosis, intestinal damage, inflammation, ineffective pathogen control, and increased mortality in sepsis. The striking impact of claudin-2 deletion on progression of the lethal cascade activated during sepsis suggests that claudin-2 may be an attractive therapeutic target in septic patients.

Indexed as

Claudin-2SepsisAnimalsClaudinsDysbiosisHumansIntestinal Barrier FunctionIntestinal MucosaMicePermeabilityTight JunctionsUp-RegulationClaudin-2ClaudinsCldn2 protein, mousebarriergutintestinesepsistight junction

Identifiers

PMID38412124
PMCPMC10927519
OpenAlexW4392189636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.